NPC1L1 and type 2 diabetes mellitus: However, clinical trials of other LDL-C lowering agents (including PCSK9 inhibitors [3], NPC1L1 inhibitors [4], and bempedoic acid [5] have not demonstrated increases in T2D risk, and genetic associations of variants in corresponding gene regions show between-region heterogeneity in their associations with T2D risk [19, 20].